Primary Hyperparathyroidism (PHPT) is a common condition affecting up to 4 per 1000 individuals, and the majority of cases are due to adenoma or hyperplasia of the gland (
6).
Although primary Hyperparathyroidism (PHPT) is asymptomatic in most patients, its main clinical manifestation is nephrolithiasis (
5).
In a reported case series about nephrolithiasis, incidence of PHPT was 2% to 8% (
7). More than 50% of cases with hyperparathyroidism had renal manifestations, such as nephrolithiasis and nephrocalcinosis (
8).
One of the clinical manifestations in symptomatic patients, who had no previous history of renal disorder, was nephrolithiasis. Other involvements were in cardiovascular, neuromuscular, and gastrointestinal systems, with different symptoms (
9). The classic manifestations of hyperparathyroid bone disease are osteitis fibrosa and brown tumors (
1).
In symptomatic pHPT, proximal muscles weakness can occur, which is accompanied by progressive fatigue and malaise (
10).
The most important renal manifestation of PHPT is nephrolithiasis, chronic renal insufficiency, and a variety of abnormalities in renal tubular function, particularly decreased concentrating ability (
1). About 20% of patients with PHPT have nephrolithiasis caused by chronic hypercalcemia (
11). Nephrolithiasis is considered as a risk factor for chronic kidney disease; patients with kidney stone that develop chronic kidney disease correspond from 0.8% to 17.5%. Renal failure in patients with nephrolithiasis results from various factors, including obstructive uropathy, recurrent urinary tract infection, frequent surgeries, and coexistent medical diseases (
12).
Besides urological procedures themselves, especially surgery, can damage the renal parenchyma, especially if interventions are repeated (
13). Deposition of crystals in the tubules and interstitium of the kidneys is another mechanism for renal injury, mainly observed in patients with genetically transmitted metabolic disorders (
13).
Solitary parathyroid adenoma accounts for 85% of cases of PHPT (
14). The diagnosis of the disease is based on high normal calcium or hypercalcemia with lower normal limit phosphorous and high alkaline phosphatase and finally high PTH values (
1).
The guidelines for treatment of asymptomatic PHPT is surgical intervention in patients, who have serum calcium level > 1 mg/dL above the upper limit of normal, renal stone, and a glomerular filtration rate (GFR) less than 60 mL/minute (
15).
In the current case, the patient had renal insufficiency, urolithiasis, increased serum calcium level and parathyroid adenoma, thus underwent parathyroid gland resection.
The diagnosis could be delayed due to nonspecific involvements in several systems, including the urinary, neuralgic, gastrointestinal, and musculoskeletal system. In the present case, the patient had neglected to evaluate the etiologies of recurrent nephrolithiasis and metabolic investigation for 6 years, and the renal outcome was due to late diagnosis.
3.1. Conclusion
More attention must be paid to patients with recurrent nephrolithiasis, and such patients must be evaluated for PHPT before progressing to CKD. Also, routine serum calcium measurement are recommended to determine the cases of this disease in its earlier stages before the start of complications.